Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 6Active not recruiting 6Completed 4Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 3Neoplasms 2Melanoma 2Vulvar Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Skin Neoplasms 1Recurrence 1Rectal Neoplasms 1Penile Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Disease Progression 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma 1Advanced Squamous Non-Small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

Exercise 9Standard of Care 5trametinib 3tislelizumab 3Radiotherapy 3Radiosurgery 3Palliative Care 3Paclitaxel 3Gemcitabine 3Carboplatin 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2cemiplimab 2Therapeutics 2Surveys and Questionnaires 2Resistance Training 2Oxaliplatin 2Maintenance 2Immune Checkpoint Inhibitors 2Drug Therapy 2Cisplatin 2Anastrozole 2vedolizumab 1toripalimab 1surufatinib 1sparsentan 1sintilimab 1semaglutide 1posaconazole 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasms × cemiplimab × Clear all
NCT07567469 2026-05-05

A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

Regeneron Pharmaceuticals

Phase 1/2 Not yet recruiting
120 enrolled
CNS

Ependymoma, Glioma, Neoplasms, Recurrence

NCT07274384 2025-12-10

HYPERBOLIC

Università Vita-Salute San Raffaele

Phase 2 Not yet recruiting
74 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡